Needham Maintains Buy on Revance Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Revance Therapeutics (NASDAQ:RVNC) but has reduced the price target from $25 to $20.
January 09, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Needham analyst reaffirms Buy rating on RVNC but lowers price target to $20, indicating a potential downside compared to the previous target.
The reduction in price target by Needham suggests a reassessment of RVNC's future price potential, likely due to updated analysis of the company's prospects or market conditions. While the Buy rating indicates continued optimism about the company's performance, the lower price target may lead to short-term negative sentiment among investors, potentially impacting the stock price negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100